33.22

5.39% 1.70

Pre-market: 34.00 0.78 +2.35%

Kodiak Sciences Inc (KOD)

Overview News Price History Option Chain Financials Discussions Forecast

Kodiak Sciences Inc stock is traded at $33.22, with a volume of 1.29M. It is up +5.39% in the last 24 hours and down -10.75% over the past month. Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Previous Close:

$31.52

Open:

$30.9

24h Volume:

1.29M

Relative Volume:

1.82

Market Cap:

$2.09B

Revenue:

Net Income/Loss:

$-230.66M

P/E Ratio:

-7.9584

EPS:

-4.1742

Net Cash Flow:

$-148.12M

1W Performance:

+1.13%

1M Performance:

-10.75%

6M Performance:

+52.04%

1Y Performance:

+114.46%

1-Day Range:

$29.81

$33.77

1-Week Range:

$29.81

$34.48

52-Week Range:

$10.94

$47.84

Kodiak Sciences Inc Stock (KOD) Company Profile

Name

Kodiak Sciences Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

650-281-0850

Address

1250 PAGE MILL RD, PALO ALTO, CA

Employee

124

Twitter

@kodiaksciences

Next Earnings Date

2026-11-12

Latest SEC Filings

KOD's Discussions on Twitter

Compare KOD vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KOD Kodiak Sciences Inc	33.22	2.09B	0	-230.66M	-148.12M	-4.1742
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-25-25	Upgrade	Barclays	Underweight → Equal Weight
Sep-22-25	Initiated	Jefferies	Buy
Aug-14-25	Upgrade	JP Morgan	Underweight → Neutral
Dec-09-24	Upgrade	Jefferies	Hold → Buy
Sep-05-24	Initiated	H.C. Wainwright	Neutral
Dec-11-23	Resumed	Goldman	Sell
Nov-17-23	Upgrade	CapitalOne	Equal Weight → Overweight
Jul-27-23	Downgrade	UBS	Buy → Neutral
Jul-25-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Jul-25-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-23	Downgrade	CapitalOne	Overweight → Equal Weight
Jul-24-23	Downgrade	Jefferies	Buy → Hold
Nov-15-22	Initiated	CapitalOne	Overweight
Aug-02-22	Downgrade	Citigroup	Neutral → Sell
Feb-24-22	Downgrade	JP Morgan	Overweight → Neutral
Feb-11-22	Initiated	Goldman	Buy
Feb-02-22	Upgrade	JP Morgan	Neutral → Overweight
May-11-21	Upgrade	ROTH Capital	Neutral → Buy
Mar-12-21	Initiated	Evercore ISI	Outperform
Mar-01-21	Downgrade	Barclays	Equal Weight → Underweight
Feb-17-21	Downgrade	ROTH Capital	Buy → Neutral
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-17-20	Initiated	Berenberg	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-11-20	Initiated	Citigroup	Neutral
Nov-30-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-16-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-13-20	Downgrade	Goldman	Buy → Neutral
Mar-31-20	Initiated	BMO Capital Markets	Outperform
Mar-03-20	Initiated	Goldman	Buy
Feb-18-20	Downgrade	Barclays	Overweight → Equal Weight
Feb-06-20	Initiated	SunTrust	Buy
Jan-08-20	Initiated	ROTH Capital	Buy
Jan-03-20	Initiated	Jefferies	Buy
Dec-24-19	Initiated	JP Morgan	Overweight
Oct-15-19	Reiterated	Chardan Capital Markets	Buy
Feb-20-19	Initiated	Chardan Capital Markets	Buy
Oct-29-18	Initiated	Barclays	Overweight
Oct-29-18	Initiated	BofA/Merrill	Buy
Oct-29-18	Initiated	Morgan Stanley	Overweight

View All

Kodiak Sciences Inc Stock (KOD) Latest News

Sep 24, 2026

Upcoming DAYBREAK Trial Results in Wet AMD Could Be A Game Changer For Kodiak Sciences (KOD) - finance.yahoo.com

Sep 24, 2026

Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating - Investing.com

Sep 24, 2026

Goldman Sachs Reinstates Coverage on Kodiak Sciences (KOD) with Neutral Rating Amid Sector Resilience - GuruFocus

Sep 24, 2026

Kodiak Sciences (KOD) Stock Looks Overvalued After Its 15x Run - finance.yahoo.com

Sep 24, 2026

Sep 23, 2026

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research

Sep 23, 2026